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Abstract: miR-29b2 and miR-29c play a suppressive role in breast cancer progression. C1orf132 (also
named MIR29B2CHG) is the host gene for generating both microRNAs. However, the region also
expresses longer transcripts with unknown functions. We employed bioinformatics and experimental
approaches to decipher C1orf132 expression and function in breast cancer tissues. We also used the
CRISPR/Cas9 technique to excise a predicted C1orf132 distal promoter and followed the behavior
of the edited cells by real-time PCR, flow cytometry, migration assay, and RNA-seq techniques.
We observed that C1orf132 long transcript is significantly downregulated in triple-negative breast
cancer. We also identified a promoter for the longer transcripts of C1orf132 whose functionality was
demonstrated by transfecting MCF7 cells with a C1orf132 promoter-GFP construct. Knocking-out the
promoter by means of CRISPR/Cas9 revealed no alterations in the expression of the neighboring
genes CD46 and CD34, while the expression of miR-29c was reduced by half. Furthermore, the
promoter knockout elevated the migration ability of the edited cells. RNA sequencing revealed
many up- and downregulated genes involved in various cellular pathways, including epithelial to
mesenchymal transition and mammary gland development pathways. Altogether, we are reporting
here the existence of an additional/distal promoter with an enhancer effect on miR-29 generation
and an inhibitory effect on cell migration.
Keywords: lncRNA; breast cancer; TNBC; EMT; miR-29; C1orf132
1. Introduction
Breast cancer (BC) is the leading cause of cancer-related death in women worldwide,
with an estimated 2,100,000 new cases and 627,000 deaths in 2018 [1,2]. In Iran, the age
distribution of BC is nearly 10 years lower than that of counterparts in many countries [3].
Despite the increased incidence rate, BC is highly curable if diagnosed and appropriately
treated at early stages. Clinically, classification of BC is based on histopathological findings
of the patients’ tissue samples obtained through surgery or biopsy. This includes the as-
sessment of the receptor status of tumor cells, namely estrogen receptor (ER), progesterone
receptor (PR), and human epidermal growth factor receptor 2 (HER2) [4,5]. One important
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subtype of BC is triple negative BC (TNBC), in which neither of the aforementioned recep-
tors are expressed. TNBC tumors make up 10–30% of all breast cancers and are reported
to be the most aggressive form of BC, with high histological grade and increased mitotic
count, central necrosis, and margins of invasion. It is also associated with younger age of
incidence and poorer prognosis in comparison to the non-TNBC patterns [6], as well as an
association with shorter duration of breastfeeding, higher age at first pregnancy, and lower
parity [7,8].
Long non-coding RNAs (lncRNAs) are important but poorly conserved transcribed
RNA molecules with at least 200 nt in length which are involved in complex biological
as well as pathological processes. Their mechanism of action can be summarized in four
different ways: (I) serving as a signaling molecule, (II) acting as a molecular decoy and/or
sponge, (III) guiding some changes in cis or trans gene expression, and (IV) acting as
scaffolds [9,10]. Dysregulation of several lncRNAs has already been reported in breast
cancer. They exert either oncogenic or tumor-suppressive functions with significant impacts
on various biological and pathological processes, especially in the progression of malignant
tumors [11].
C1orf132 is an intergenic lncRNA located on 1q32.2 between the CD34 and CD46
protein coding genes. C1orf132 (also known as MIR29B2CHG) is the host gene for miR-29b2
and miR-29c, with a molecular size of more than 20 kb. Its promoter is more likely to be
hypermethylated in basal-like breast tumors compared to low-grade ones [12]. Bhardwaj
and colleagues used the next-generation RNA sequencing technique on a breast cancer
progression cell line model and discovered that the tumor-suppressor miR-29c is highly
downregulated during the course of breast cancer cell progression toward TNBC. Moreover,
their data revealed that higher miR-29c expression is associated with a longer survival rate
and lower distant metastasis [13].
Despite its potential importance, very little is known about the expression and function
of C1orf132 in tumor cells and tissues. Here, for the first time to our knowledge, we explored
the expression pattern of C1orf132 in different types of breast cancer cell lines and tissues.
We also identified and analyzed a distal promoter area with an enhancing function on miR-
29b2/c expression and an inhibitory effect on G2/M phase of cell cycle and cell migration.
2. Results
2.1. C1orf132 Locus and Its Transcripts
C1orf132, also known as the host gene for miR-29b2 and miR-29c, is located between
two protein coding genes, CD34 and CD46 (Figure 1). There are several transcripts with
various lengths and number of exons of MIR29B2CHG located between the two aforemen-
tioned coding genes. No ortholog gene for C1orf132 has been reported in mice, mostly
because lncRNAs are not conserved during evolution. For this reason, we searched for
potential lncRNAs overlapping with miR-29b2 and miR-29c in mouse genome. Interest-
ingly, we discovered a lncRNA with conserved chromosomal location and transcriptional
direction in reference to its human counterpart (Figure 1).
The human mir precursor has 5 or 6 exons, with its promoter located (~20 kb) upstream
of the miR29b2c (Figure 2, indicated in blue). In addition, we noticed several spliced
variants of the transcript, some with different start sites, located upstream of the known
promoter for miR-29 host gene variant. The latter finding suggested that the lncRNA could
bear more roles rather than just serving as a precursor to generate miR-29. Analysis of
the FANTOM5 data set indicated the existence of at least two additional distal potential
transcriptional start sites (p1 and p2) for the transcription of the longer forms of C1orf132,
with the putative p2 promoter containing a CpG island (Figure 2A–C). ENCODE data
exhibited the expression and chromatin modifications (H3K27ac and H3K4me3) of the
C1orf132 locus in MCF7 cells, while the active marks were mostly concentrated on two
start sites: One as the promoter of miR-29 precursor and the other one as the potential
promoter for the longer transcript (Figure 2D–G). According to the ENCODE ChIP-seq
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data, the latter promoter could interact with more than 80 different transcription factors
(Figure 2H–J).
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Expression analysis of different breast cancer subtypes in TCGA revealed a down-
regulation of the longer transcripts of C1orf132 in TNBC patients. According to the results, 
the expression level of C1orf132 transcripts originating from the p2 promoter was signifi-
cantly decreased in ER/PR negative and TNBC patients compared to the ER/PR positive 
as well as non-TNBC ones (Figure 3A). To confirm this experimentally, we performed 
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confirmed the same pattern of significant (p < 0.05) downregulation of C1orf132 in TNBC 
Figure 1. Genomic location of C1orf132 long-noncoding RNA in humans and mice. Top: The genomic
location of miR-29b2, miR-29c, and their precursor, MIR29B2CHG, in humans. As shown, the region
encoding the lncRNA is located between the CD34 and CD46 genes. Bottom: By searching the
genomic location of miR-29 in mice, we found out that the lncRNA A330023F24 is the host gene for
miR-29b-2 and miR-29c. Interestingly, the chromosomal location and transcription direction of the
lncRNA is conserved between humans and mice.
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Figure 2. The genomic features of miR29b2c precursor. To make it easier to follow, the location of
miR-29b2 and miR-29c are highlighted with yellow and purple color bands, respectively, and the
potential distal transcription start sites of MIR29B2CHG with red color bands. As it is evident in the
figure, there are several spliced variants for the miR29b2c precursor. In addition to the miR29b2c
precursor (short variants), there are also longer variants of C1orf132 (A). Other bioinformatics features
(UCSC Genome Browser hg19) support the existe ce of other start sites for C1orf132 transcription,
including: Max coun s of CAGE reads belonging to FANTOM5 summ ry (B), CpG isl nd (C),
active promoter-predicted elements according to Broad Chro HMM (D), active or potentially active
regulatory elements of layered and MCF7 cells H3K27ac mark (E,F), active or potentially active
promoter and enhancer regi ns marks by H3K4me3 and H3K4me1, respectively (G,H), DNase cluster
(I), and transcription factor ChIP (J).
2.2. C1orf132 Was Significantly Downregulated in TNBC Tissue Samples
Expression analysis of different breast cancer subtypes i TCGA evealed a downreg-
ulation of the longer transcripts of C1orf132 in TNBC patients. According to the results, the
expression level of C1orf132 transcripts originating from the p2 promoter was significantly
decreased in ER/PR negative and TNBC patients compared to the ER/PR positive as well
as non-TNBC ones (Figure 3A). To confirm this experimentally, we performed qRT-PCR
and measured the level of C1orf132 long isoform in tumor samples along with their adjacent
non-tumor tissues. The real-time PCR results on 52 paired tissue samples confirmed the
same pattern of significant (p < 0.05) downregulation of C1orf132 in TNBC vs. non-TNBC
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samples (Figure 3B). However, we found no significant correlation between this isoform
and other subtypes of breast cancer (p > 0.05).
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locations targeted with guide RNAs are depicted as guides 1–3 on putative p2 region (highlighted
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MCF12A edited cell colonies in comparison to the unedited cells is shown.
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Flow cytometry analysis revealed a reduction in cell distribution in S phases of the
cell cycle progression of the edited compared to the unedited MCF12A cells (p < 0.05,
Figure 6A). Data obtained from three different biological repeats demonstrated that the
putative p2 promoter knock-down could delay the cell cycle progression and significantly
increase the number of cells in the G2/M phase (p < 0.001, Figure 6B).
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cells edited for C1orf132 expression. (E) The expression level of miR-29c-3p in C1orf132-promoter
eliminated cells was significantly reduced by half compared to wild-type MCF12A cells. (F) Several
genes were differentially expressed in edited vs. unedited MCF12A cells; FGF2 and its receptor
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2.4. Promoter Deletion Enhanced the Migration Ability of MCF12A Cells
As seen in Figure 6, the initial scratch width was monitored in wound healing experi-
ments in edited (top) vs. unedited MCF12A cells (bottom). The results obtained at time
points 0 and 24 h revealed that the migration ability was significantly incresed in edited
cells compared to the unedited cells (p < 0.05; Figure 6C,D).
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2.5. Gene Expression Profiling after C1orf132 Knock-Down
The gene expression profiles obtained by RNA-seq in two biological replicates of
edited and wild-type cells demonstrated 1565 genes with differential expression (adjusted
p < 0.001), including 551 upregulated and 1014 downregulated genes (Supplementary
Figure S1A). Moreover, two-dimensional PCA graph of the data for the two replicates of
C1orf132 edited and unedited MCF12A cells showed nicely separated replicates of edited
cells from wild-type cells (Supplementary Figure S1B). Accordingly, the same data emerged
from the heatmap of differentially expressed genes between edited and unedited MCF12A
cells (Supplementary Figure S1C).
As lncRNAs could have a general enhancer role on neighboring genes, we first looked
at any potential altered expression of upstream and downstream genes of the edited region.
According to the RNA-seq analysis, the two neighboring genes, CD34 and CD46, were
not affected in the edited cells, however, the expression of mir29b2c precursor declined
in edited cells compared to the wild-type cells (p < 0.001; Figure 6E). According to GO
results, the differential expression analysis of the RNA-seq data revealed several up- and
downregulated genes involved in various biological processes, including the positive
regulation of vascular endothelial cell proliferation and regulation of endothelial cell
chemotaxis to fibroblast growth factor biological processes. FGF2 (p < 0.01) and FGFR1
(p = 0.19) genes, which are responsible for the abovementioned processes, were upregulated
more than four-fold in edited cells (Figure 6F). FGF2 is a tumor cell survival factor that
helps cells to escape apoptosis. Moreover, in the edited cells the expression fold change for
CDH2 (N-Cadherin) as a mesenchymal marker was elevated more than twelve-fold (p < 0.05)
compared to the unedited cells. In contrast, the expression of CDH1 (E-Cadherin) as an
epithelial marker was noticeably downregulated in edited cells (p < 0.001) compared to the
wild-type MCF12A cells. Here, ZEB1 as an EMT transcription factor showed about 13-fold
upregulation in edited cells (p < 0.01; Figure 6F). ESR1, the gene coding for estrogen receptor
alpha (ERα), was downregulated (p < 0.001), along with gap junction β-2 (GJB2/CX26;
p = 0.27) and WNT4 (p < 0.001) in edited MCF12A cells to near zero.
3. Discussion
lncRNAs are the largest class of transcripts in human cells, and also the least under-
stood ones. Among various mechanisms attributed to them, being the host of small RNAs,
including miRNAs, is the best-known function of these regulatory molecules. However, it
is not clear if this type of lncRNAs have additional functions other than being simply the
host genes for small RNAs. C1orf132 or MIR29B2CHG is the host gene of two important
miRNAs, miR-29b2 and miR-29c. Here, we investigated whether this lncRNA could also
have other functions in human breast cancer cells.
There are few reports on C1orf132 gene and its cellular role. C1orf132 has been reported
as one of five candidate genes whose CpG island methylation are being used to predict
an individual’s age in forensic medicine [14,15]. Indeed, the C1orf132 gene provided the
highest accuracy in predicting age [16].
In contrast to coding genes, long non-coding genes have low conservation during
evolution, which makes it difficult to find their orthologs in other species. Here, we
used a simple logic to find the C1orf132 ortholog gene in mice by looking at genomic
location of mice miR-29b2 and miR-29c. As we expected, there was a lncRNA gene in mice
hosting both miRNAs. Surprisingly, C1orf132 and its mouse counterpart have an exact
chromosomal position, located between the CD34 and CD46 genes, and are transcribed
in the same direction in relation to their neighboring genes. Although there is no need
for positional genomic conservation of ortholog miRNA host genes, this evolutionary
conservation suggests that C1orf132 might have other functions in addition to being a host
gene for miR-29b2c.
Our in-silico studies revealed two potential promoters in addition to the previously
known miRNAs precursor promoter [12], as well as two groups of long and short transcripts
for C1orf132. The reason for generating short and long transcripts of the gene is not known,
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however, we observed a similar pattern of short and long transcripts for PSORS1C3
lncRNA in our previous study [17]. There is a possibility that this kind of gene expression
regulation by alternative splicing in a tissue- and cell-specific manner is a more general
feature of lncRNAs, and their possible dysregulation could contribute to pathogenesis
of many cancers [18]. To explore potential functions of the long transcripts of C1orf132,
we suppressed their expression by excising the distal promoter by CRISPR/Cas9. It has
been already claimed that lncRNAs could have an enhancer effect on their neighboring
genes [19]. However, we observed no changes in the expression level of CD34 and CD46 in
edited cells, both in our RNA-seq and real-time PCR data, ruling out an enhancer role of this
sequence on its neighboring genes. Interestingly, there exists a significant downregulation
of miR-29c-3p in edited cells, suggesting an enhancer role of the distal promoter on the
proximal promoter of the gene. The latter finding makes it very difficult to interpret the
RNA-seq results of the edited cells. Indeed, it is impossible to discriminate the direct
effects of C1orf132 from an indirect effect mediated by altered expression of miR-29b2
and miR-29c.
In a bioinformatics analysis of 20 published studies, Yan and colleagues reported
that the low expression of miR-29a/b/c is associated with poor prognosis of malignant
neoplasms and could be used as a key biomarker to predict cancer progression and recur-
rence [20]. Furthermore, these miRNAs exhibit both tumor suppressive and oncogenic
roles in different cancers. This might be due to the differences in sample types, location,
size, or the period of follow-up studies [20–22].
We also observed an enhanced migration ability in edited cells, suggesting an invasion
suppressor role for C1orf132. This is in agreement with Zhang et al. who reported a
significant increase in invading cells emerging in miR-29-suppressed HepG2 cells [23].
Jiang et al. reported that miR-29c was remarkably decreased in pancreatic cancer cells and
that it had an association with shorter overall survival and tumor recurrence in pancreatic
cancer patients [24]. It has been well documented that miR-29c is lost as early as the
preneoplastic stage of TNBC tumorigenesis, where its downregulation could cause a worse
overall survival via regulating several target genes [13].
EMT is characterized by a loss of function of the E-cadherin adhesion protein (CDH1)
in epithelial tissues; breast cancer is a good example of this process. In addition to their
role in normal cells, classical cadherins (E- and N-cadherins) have a distinguished role in
transforming malignant cells as well as tumor progression, in a process termed “cadherin
switching” [25,26]. This process is regulated by EMT transcription factors, including
the ZEB family. ZEB1 and ZEB2 are EMT transcription factors which synergistically
increase tumor invasion and cell migration [27]. ZEB1 helps epigenetic silencing of CDH1
by bringing several enzymes to the E-cadherin promoter for epigenetic induction or by
inhibiting the expression of stemness-repressing miRNAs to cause a dynamic transition of
non-cancerous stem cells into cancer stem cells (CSCs) and vice versa [28,29]. In this study,
we demonstrated that a cadherin switching evidently took place through a downregulation
of CDH1 and an upregulation of CDH2 by almost 12-fold, as well as by an almost 14-fold
overexpression of ZEB1.
Interaction of N-cadherin (CDH2) and FGF receptor (FGFR) leads to their stabiliza-
tion on the cell surface. In this way, N-cadherin increases tumor cell interactions with
endothelial and mesenchymal cells [25]. On the other hand, fibroblast growth factor 2
(FGF2), which can induce proliferation of neoplastic cells and hormone independent tumor
growth [30], is a tumor cell survival factor that inhibits cell apoptosis through an autocrine
secretory loop. In addition, FGF2 can be an activator of angiogenesis during tumor mass
growth and metastasis [31]. In this study, we demonstrated that FGF2 and FGFR1 were
differentially overexpressed in edited MCF12 cells by almost four-fold. By these results,
the pathway analysis of our data by Enrichr was nicely validated for upregulated genes.
On the contrary, we evaluated the expression of ESR1, GJB2, and WNT4 genes using
qRT-PCR and found that these genes are expressed at very low (near zero) levels in edited
cells. GJB2 and ESR1, with a role in “mammary gland development pathway-pregnancy
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and lactation,” according to WikiPathways, were among the significantly downregulated
genes in edited MCF12A cells. Estrogen receptor α (encoded by ESR1), which is expressed
in normal breast epithelium, has an essential growth and differentiation role. It is also
associated with the growth and survival of breast epithelial cancer cells [32], as well as
playing a role in the initiation and progression of estrogen-dependent breast cancers [33]. As
mentioned earlier, a significant progressive loss of miR-29c, as a result of breast cancer cell
line progression model to TNBC, was expected [13]. Therefore, a decline in ESR1 expression
is in line with miR-29c downregulation, which we have observed in our edited cells. We
also observed a reduction of GJB2 in our edited cells. GJB2 encodes a member of the gap
junction protein family often found in the epithelial cells of the mammary duct (luminal)
and can form a gap connection channel in the form of homodimers or heterodimers [34].
In breast cancer, the protein was shown to be a tumor-suppressor gene and its very low
expression in breast tumor cells might be associated with hypermethylation [35].
Our results revealed a downregulation of WNT4 in C1orf132 knocked-down MCF12A
cells. Wnt-4 is a member of the WNT family, which encodes important signaling pro-
teins and plays a vital role in some developmental and oncological processes. Several
reports have shown an association of Wnt-4 to epithelial cells, such as its expression in
normal murine keratinocytes [36], and also throughout skin [37] and mammary gland
development [38]. Saitoh and colleagues reported that in keratinocyte cell lines, a poor
differentiation and more malignant phenotype is related to the loss of Wnt-4 gene ex-
pression [36]. In another study, a similar association between Wnt4 and mesenchymal to
epithelial transition during kidney development has been shown [39]. In contrast, Vouy-
ovitch and colleagues reported that depletion of WNT4 in MCF12 cells inhibited cellular
proliferation. Moreover, upregulated WNT4 in non-malignant breast cells stimulated
growth, inhibited apoptosis, and increased cell migration and EMT [40].
As the only reference on C1orf132 lncRNA and cancer, Peng et al. detected two
lncRNAs (C1orf132 and TMPO-AS) as a prognostic signature for lung adenocarcinoma
patients. By pathway analysis, they suggested that a downregulation of C1orf132 was
associated with a poor prognosis in lung cancer patients, probably by deregulating the
“cell cycle and cell adhesion molecules” pathways in cancer cells [41]. Finally, our qRT-PCR
data on C1orf132 knocked-down cells were in line with the RNA-seq and bioinformatics
data. Altogether, our data suggest a dysregulated cell cycle and cell adhesion in breast cell
line, which might be the cause of aberrant migration of edited MCF12 cells.
As mentioned before, the miR29b2/c precursor is transcribed by the proximal pro-
moter of the gene. To differentiate between the function of C1orf132 and those of miR29b2/c,
we excised the distal promoter of the gene responsible for the generation of longer tran-
scripts of C1orf132. Nevertheless, our data revealed that the distal promoter, and hence the
longer transcripts, have an enhancing effect on the proximal promoter. Therefore, some of
our obtained functional analysis data in the edited cells could simply be some unavoidable
secondary effects of the distal promoter on miR29b2/c expression alteration. A precise dif-
ferentiation between the function of c1orf132 and those of miR-29b2 and miR-29c requires
more experiments, including miR-29b2 and miR-29c knockout and/or their overexpression
in C1orf132 knockout cells.
4. Materials and Methods
4.1. Ethical Statement
This research involved collecting human tissues from Khatam-ol-Anbia and Rasule-
Akram hospitals with no experimenting on human subjects or animals. In vitro experiments
on commercial cell lines and pathological samples were approved by Ferdowsi University
of Mashhad (code number: IR.UM.REC.1399.104). The patients’ written informed consents
were collected prior to participation.
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4.2. Clinical Tissue Samples
In this study, a total number of 52 pathological tissue samples with a diagnosis
of primary breast cancer were collected. None of the patients had been treated with
preoperative radiotherapy, chemotherapy, or other relevant modalities. Breast cancer
tissue samples along with their matched adjacent apparently normal tissues were collected,
immediately preserved in liquid nitrogen, and then stored at −80 ◦C until analysis. All
patients signed informed consents and agreed to the use of their surgical specimens
for research.
4.3. Bioinformatics Analysis
We used the UCSC genome browser to scan the genomic area around C1orf132 (located
at chr1: 207,978,592–208,052,441 (hg19)) for potential promoter activity. Histone modifi-
cations by ChIP-seq from ENCODE (H3K27ac and H3K4me3) and DNA-seq were used
to detect the active area near the transcription start site (TSS). Using ENCODE ChIP-seq
data for different transcription factors (TFs), a list of TFs which bind to C1orf132 potential
promoters was extracted. FANTOM5 data were used to determine which genomic regions
the reads originated from.
To evaluate the correlation of C1orf132 transcripts originating from the putative
p2/distal promoter with the tumor state of breast tissues, we performed data mining
of The Cancer Genome Atlas (TCGA) breast cancer subtypes to study their association with
the expression level of C1orf132.
4.4. Cloning the Putative Promoters of C1orf132
The potential promoter regions (p1 and p2) for C1orf132, according to the bioinformat-
ics analysis, were amplified from genomic DNA using Accu Taq polymerase kit (Invitrogen,
Carlsbad, CA, USA) and specific primers (Supplementary Table S1). The amplified products
(1203 bp for p1 and 2143 bp for p2), were cloned into the promoterless green fluorescent
protein (pEGFP-1) reporter vector using flanking sequences on primers for AgeI/SalI restric-
tion sites (Supplementary Table S1). The accuracy of the cloned constructs was confirmed
by DNA sequencing (Eurofins Genomics Service, Milan, Italy).
4.5. Cell Culture and Transfection
MCF7 cell line was cultured in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.
MCF12A cells were cultivated in a special medium containing DMEM/F12 (Thermo Fisher
Scientific, Waltham, MA, USA), 5% heat inactivated horse serum (Gibco, Grand Island, NY,
USA), 20 ng/mL recombinant human EGF (AF100-15 Peprotech, Rocky Hill, NJ, USA),
0.5 µg/mL hydrocortisone, 100 ng/mL cholera toxin (C-8052, Sigma, St. Louis, MO, USA),
10 µg/mL human recombinant insulin (Zinc solution 12585-014, Gibco, TN, USA), and 1%
penicillin/streptomycin and incubated at 37 ◦C with 5% humified CO2. To examine the
promoter activity of the cloned regions, the recombinant vectors were used to transfect
MCF7 cells. All experiments were done with complete medium in at least triplicates.
4.6. Fractionation Assay
We examined the nuclear vs. cytoplasmic subcellular localization of C1orf132 in
MCF12A cells by fractionation with cell fractionation buffer (Ambion, Austin, TX, USA),
according to the manufacturer’s instructions. RNA was extracted to assess the relative
proportion of C1orf132 in the nuclear and cytoplasmic fractions. The transcription levels
of beta 2-microglobulin (B2M) as a cytoplasmic marker, U1 as a nuclear marker, and
C1orf132 were then assessed using quantitative reverse transcription-polymerase chain
reaction (qRT-PCR).
Int. J. Mol. Sci. 2021, 22, 6768 11 of 14
4.7. Promoter Activity Reporter Assay
MCF7 cells were seeded in 48-well plates (SPL Life Sciences, Pocheon-si, South Ko-
rea). After complete adhesion, cells were transfected with 1 µg of vector (pEGFP-1-p1 or
pEGFP-1-p2) using Lipofectamine LTX & PLUS reagent (Invitrogen, Carlsbad, CA, USA),
according to the manufacturer’s instructions. pEGFP-1 is a promoterless vector containing
an eGFP reporter. The presence of the GFP signal was monitored in MCF7 cells transfected
with pEGFP-C1 as the positive control and pEGFP-1-p1 or pEGFP-1-p2 vectors 48 h after
transfection and under a fluorescent microscope.
4.8. Promoter Deletion Using CRISPR/Cas9 System
In order to suppress C1orf132 expression, we decided to delete its p2 promoter using
the CRISPR/Cas9 system. Three pairs of different guide RNAs (gRNAs) were designed
(Supplementary Table S1) to target the putative sequences of the p2 transcription start site,
using http://crispr.mit.edu (accessed on 5 June 2021). The three gRNAs were then cloned
into TOPO-TA gRNA vectors. Briefly, guide RNA plasmid backbone (TOPO-TA gRNA) was
linearized using the BbsI enzyme (New England Biolabs, Beverly, MA, USA) and digested at
37 ◦C for 1 h. Annealing took place using sense and anti-sense oligonucleotides in buffer 2
(NEB), before placing the reaction in a thermocycler with the ramp of 0.1 ◦C/s from 95 ◦C
to 25 ◦C. To ligate the gRNA within the linearized vector, T4 DNA ligase (Thermo Fisher
Scientific, USA) was used and the reaction was incubated at room temperature for 60 min.
Then, E. coli cells were transformed with gRNA vectors using heat-shock protocol followed
by plating the cells on LB/ampicillin (100 µg/mL) plates overnight. Colony-PCR was
performed to verify the sequence of the gRNA plasmids using the reverse oligo of guides
and forward primer of TOPO vector.
Different pairs of gRNA-containing vectors were co-transfected along with wild type-
Cas9 vector (PX458) into MCF12A cells by lipofectamine LTX & PLUS reagent (Invitrogen,
USA). Single cells expressing GFP were selected by a cell sorter machine (BD FACSCelesta)
24 h after transfection. Edited colonies were investigated for deletion by DNA extraction
using Puregene Core kit A (Qiagen, Valencia, CA, USA), according to the manufacturer’s
instructions, followed by performing PCR using flanking primers (Edited-Test) and DNA
sequencing (Europhins, Italy).
4.9. Wound Healing Assay
Edited and unedited MCF12A cells were seeded into 24-well plates (with 6 repeats)
and grew to 90% confluency. The monolayers were scratched using a 200 µL pipette tip
and then the floating cells were removed by several washes with phosphate buffered saline
(PBS). Subsequently, the cells were incubated at 37 ◦C for 24 h before being photographed.
The migration area of wound healing was border-lined and analyzed using the ImageJ
software (NIH, Bethesda, MD, USA).
4.10. Cell Cycle Analysis by Flow Cytometry
Triplicates of three different densities (10,000, 20,000, and 30,000) of edited vs. unedited
MCF12A cells were seeded into 12-well plates. The Vybrant™ DyeCycle™ Violet Stain kit
(Invitrogen, USA), which is capable of entering living cells and staining DNA, was used to
examine the cell cycle 24 h later. Briefly, cells were washed in cold PBS and then harvested
and resuspended in the complete medium. Next, flow cytometry tubes each containing
1 mL of cell suspension in complete medium at a concentration of 1 × 106 cells/mL were
prepared. In total, 1 µL of Vybrant™ DyeCycle™ Violet Stain was added to each tube
(final concentration of 5 µM) and mixed well. After 1 h incubation at 37 ◦C with protection
from light, the samples were analyzed without washing or fixing on a flow cytometer (BD
FACSCelesta) using a laser beam.
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4.11. RNA Extraction and qRT-PCR
A small amount of frozen patient tissue samples was lysed for RNA extraction using
RNSol (ROJE, Yazd, Iran) or QIAZOL (Qiagen, USA). Total RNA was extracted according
to the manufacturer’s instructions. In total, 1 µg of RNA was first treated with DNase I
(Thermo Fisher Scientific, USA) in order to eliminate any traces of DNA contamination
and then reverse transcribed using PrimeScript first strand cDNA synthesis kit (TaKaRa,
Tokyo, Japan). The expression of target genes was evaluated using BioFACT™ 2X real-time
PCR master mix (BioFact, Daejeon, South Korea) through the ABI StepOne real-time PCR
system. The sequence of primers used for quantifying each target gene can be found
in Supplementary Table S1. Relative expression of target genes to B2M was calculated
according to 2−∆∆Ct method. For the cells, the expression of target genes was evaluated
using SensiFAST SYBR No-ROX one-step kit (Bioline Cat. No: BIO-72001, Taunton, MA,
USA), according to the manufacturer’s instructions. In total, 30 ng of RNA was used in a
one-step real-time PCR using the Rotor-Gene instrument (Qiagen, USA).
4.12. TaqMan miR Assay for miR-29c-3p Detection
Hsa-miR-29c-3p (ID 000587) and U6 snRNA (ID 001973) TaqMan miR assays were
ordered from Applied Biosystems (Foster City, CA, USA). Total RNA extraction followed
by qRT-PCR assay was performed to determine the expression level of miR-29c-3p in edited
versus unedited MCF12A cells, according to the manufacturer’s protocol. Briefly, total RNA
extraction was performed by Qiazol (Qiagen, USA), followed by reverse transcription using
SuperScript II Reverse Transcriptase (Thermo Fisher Scientific, USA), before completing
qPCR using Taqman® Universal PCR Master Mix II (Thermo Fisher Scientific, USA). The
samples were then incubated for 10 min at 95 ◦C for initial denaturation and subjected
to 40 PCR cycles, each consisting of 95 ◦C for 15 s and 60 ◦C for 60 s. U6 was used as the
internal control of miR-29c-3p. The 2−∆∆Ct method was used to analyze microRNA levels.
4.13. Statistical Analysis
All statistical analyses were performed using GraphPad Prism (GraphPad Software,
Inc., La Jolla, CA, USA). Student’s t-test was employed to investigate the significance of
observed differences of gene expression alterations. All tests were done in 3 biological
repeats and values are reported as mean ± standard deviation (SD). p values less than 0.05
were considered as statistically significant.
5. Conclusions
In summary, using bioinformatics and experimental tools, we discovered the following
novel findings: (1) a significant downregulation of the C1orf132 in triple-negative types
of breast cancer; (2) a mouse ortholog of C1orf132 is located at a similar genomic location
as its human counterpart; (3) an additional/distal promoter of C1orf132 with an enhancer
effect on miR-29c generation and an inhibitory effect on cell migration; (4) RNA-seq data
on distal promoter excised cells revealed many genes with altered expression involved in
various cellular pathways, including mammary gland development.
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15. Zbieć-Piekarska, R.; Spólnicka, M.; Kupiec, T.; Parys-Proszek, A.; Makowska, Z.; Pałeczka, A.; Kucharczyk, K.; Płoski, R.;
Branicki, W. Development of a foren-sically useful age prediction method based on DNA methylation analysis. Forensic Sci. Int.
Genet. 2015, 17, 173–179. [CrossRef] [PubMed]
16. Jung, S.E.; Lim, S.M.; Hong, S.R.; Lee, E.H.; Shin, K.J.; Lee, H.Y. DNA methylation of the ELOVL2, FHL2, KLF14,
C1orf132/MIR29B2C, and TRIM59 genes for age prediction from blood, saliva, and buccal swab samples. Forensic Sci.
Int. Genet. 2019, 38, 1–8. [CrossRef] [PubMed]
17. Mirzadeh Azad, F.; Malakootian, M.; Mowla, S.J. lncRNA PSORS1C3 is regulated by glucocorticoids and fine-tunes OCT4
expression in non-pluripotent cells. Sci. Rep. 2019, 9, 8370. [CrossRef]
18. Ma, X.; Zhang, W.; Zhang, R.; Li, J.; Li, S.; Ma, Y.; Jin, W.; Wang, K. Overexpressed long noncoding RNA CRNDE with distinct
alternatively spliced isoforms in multiple cancers. Front. Med. 2018, 13, 330–343. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 6768 14 of 14
19. Dennis, M.K.; Field, A.S.; Burai, R.; Ramesh, C.; Whitney, K.; Bologa, C.G. Long non-coding RNAs with enhancer-like function in
humans. Cell 2012, 127, 358–366.
20. Qi, Y.; Huang, Y.; Pang, L.; Gu, W.; Wang, N.; Hu, J.; Cui, X.; Zhang, J.; Zhao, J.; Liu, C.; et al. Prognostic value of the MicroRNA-29
family in multiple human cancers: A meta-analysis and systematic review. Clin. Exp. Pharmacol. Physiol. 2017, 44, 441–454.
[CrossRef]
21. Zhu, W.; He, J.; Chen, D.; Zhang, B.; Xu, L.; Ma, H.; Liu, X.; Zhang, Y.; Le, H. Expression of miR-29c, miR-93, and miR-429 as
Potential Biomarkers for Detection of Early Stage Non-Small Lung Cancer. PLoS ONE 2014, 9, e87780. [CrossRef]
22. Arechaga-Ocampo, E.; Lopez-Camarillo, C.; Villegas-Sepulveda, N.; Gonzalez-De la Rosa, C.H.; Perez-Añorve, I.X.;
Roldan-Perez, R.; Flores-Perez, A.; Peña-Curiel, O.; Angeles-Zaragoza, O.; Corona, R.R.; et al. Tumor suppressor miR-
29c regulates radioresistance in lung cancer cells. Tumor Biol. 2017, 39, 1010428317695010. [CrossRef]
23. Zhang, N.-S.; Dai, G.-L.; Liu, S.-J. MicroRNA-29 family functions as a tumor suppressor by targeting RPS15A and regulating cell
cycle in hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2017, 10, 8031–8042.
24. Jiang, J.; Yu, C.; Chen, M.; Zhang, H.; Tian, S.; Sun, C. Reduction of miR-29c enhances pancreatic cancer cell migration and stem
cell-like phenotype. Oncotarget 2014, 6, 2767–2778. [CrossRef]
25. Wheelock, M.J.; Shintani, Y.; Maeda, M.; Fukumoto, Y.; Johnson, K.R. Cadherin switching. J. Cell Sci. 2008, 121, 727–735. [CrossRef]
26. Afzal Ashaie, M.; Hoque Chowdhury, E. Cadherins: The Superfamily Critically Involved in Breast Cancer. Curr. Pharm. Des.
2016, 22, 616–638. [CrossRef]
27. Zhang, Y.; Xu, L.; Li, A.; Han, X. The roles of ZEB1 in tumorigenic progression and epigenetic modifications. Biomed. Pharmacother.
2019, 110, 400–408. [CrossRef] [PubMed]
28. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.;
zur Hausen, A.; et al. The EMT-activator ZEB1 promotes tumor-igenicity by repressing stemness-inhibiting microRNAs. Nat. Cell
Biol. 2009, 11, 1487–1495. [CrossRef] [PubMed]
29. Chaffer, C.L.; Marjanovic, N.D.; Lee, T.; Bell, G.; Kleer, C.G.; Reinhardt, F.; D’Alessio, A.C.; Young, R.A.; Weinberg, R.A. Poised
Chromatin at the ZEB1 Promoter Enables Breast Cancer Cell Plasticity and Enhances Tumorigenicity. Cell 2013, 154, 61–74.
[CrossRef] [PubMed]
30. Giulianelli, S.; Riggio, M.; Guillardoy, T.; Pérez Piñero, C.; Gorostiaga, M.A.; Sequeira, G.; Pataccini, G.; Abascal, M.F.; Toledo, M.F.;
Jacobsen, B.M.; et al. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and
PRB∆4 isoform to MYC regulatory sequences. Int. J. Cancer 2019, 145, 1874–1888. [CrossRef]
31. Yu, P.-J.; Ferrari, G.; Galloway, A.C.; Mignatti, P.; Pintucci, G. Basic fibroblast growth factor (FGF-2): The high molecular weight
forms come of age. J. Cell Biochem. 2007, 100, 1100–1108. [CrossRef] [PubMed]
32. Carausu, M.; Bidard, F.-C.; Callens, C.; Melaabi, S.; Jeannot, E.; Pierga, J.-Y.; Cabel, L. ESR1 mutations: A new biomarker in breast
cancer. Expert Rev. Mol. Diagn. 2019, 19, 599–611. [CrossRef]
33. Tomita, S.; Zhang, Z.; Nakano, M.; Ibusuki, M.; Kawazoe, T.; Yamamoto, Y.; Iwase, H. Estrogen receptor a gene ESR1 amplification
may predict endocrine therapy responsiveness in breast. Cancer Sci. 2009, 100, 1012–1017. [CrossRef]
34. Teleki, I.; Szasz, A.M.; Maros, M.E.; Gyorffy, B.; Kulka, J.; Meggyeshazi, N.; Kiszner, G.; Balla, P.; Samu, A.; Krenacs, T.; et al.
Correlations of Differentially Expressed Gap Junction Connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with Breast Cancer Progression
and Prognosis. PLoS ONE 2014, 9, e112541. [CrossRef] [PubMed]
35. Shettar, A.; Damineni, S.; Mukherjee, G.; Kondaiah, P. Gap junction β-2 expression is negatively associated with the estrogen
receptor status in breast cancer tissues and is a regulator of breast tumorigenesis. Oncol. Rep. 2018, 40, 3645–3653. [CrossRef]
[PubMed]
36. Saitoh, A.; Hansen, L.A.; Vogel, J.C.; Udey, M.C. Characterization of Wnt gene expression in murine skin: Possible involvement of
epidermis-derived Wnt-4 in cutaneous epithelial-mesenchymal interactions. Exp. Cell Res. 1998, 243, 150–160. [CrossRef]
37. Reddy, S.; Andl, T.; Bagasra, A.; Lu, M.M.; Epstein, D.J.; Morrisey, E.E.; Millara, S.E. Characterization of Wnt gene expression in
developing and postnatal hair follicles and identification of Wnt5a as a target of Sonic hedgehog in hair follicle morphogenesis.
Mech Dev. 2001, 107, 69–82. [CrossRef]
38. Heikkil, M.; Peltoketo, H.; Vainio, S. Wnts and the female reproductive system. J. Exp. Zool. 2001, 290, 616–623. [CrossRef]
39. Stark, K.; Vainio, S.; Vassileva, G.; McMahon, A.P. Epithelial transformation of metanephric mesenchyme in the developing
kidney regulated by Wnt-4. Nat. Cell Biol. 1994, 372, 679–683. [CrossRef] [PubMed]
40. Vouyovitch, C.M.; Perry, J.K.; Liu, D.-X.; Bezin, L.; Vilain, E.; Diaz, J.-J.; Lobie, P.E.; Mertani, H.C. WNT4 mediates the autocrine
effects of growth hormone in mammary carcinoma cells. Endocr. Relat. Cancer 2016, 23, 571–585. [CrossRef]
41. Peng, F.; Wang, R.; Zhang, Y.; Zhao, Z.; Zhou, W.; Chang, Z.; Liang, H.; Zhao, W.; Qi, L.; Guo, Z.; et al. Differential expression
analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Mol. Cancer 2017, 16, 1–12.
[CrossRef] [PubMed]
